Systemic hedgehog inhibitors to treat locally advanced basal cell carcinomas of the head–neck region: A retrospective study
暂无分享,去创建一个
[1] I. Zalaudek,et al. Management of locally advanced basal cell carcinoma treated with sonidegib: The experience of an Italian reference hospital , 2020, Dermatologic therapy.
[2] G. Fabbrocini,et al. Complete remission of an advanced basal cell carcinoma after only 3‐month treatment with sonidegib: Report of a case and drug management during COVID‐19 pandemic , 2020, Dermatologic therapy.
[3] A. Orlandi,et al. High-Risk Recurrence Basal Cell Carcinoma: Focus on Hedgehog Pathway Inhibitors and Review of the Literature , 2020, Chemotherapy.
[4] E. Campione,et al. Arsenic Trioxide, Itraconazole, All-Trans Retinoic Acid and Nicotinamide: A Proof of Concept for Combined Treatments with Hedgehog Inhibitors in Advanced Basal Cell Carcinoma , 2020, Biomedicines.
[5] G. Fabbrocini,et al. Sonidegib: Safety and Efficacy in Treatment of Advanced Basal Cell Carcinoma , 2020, Dermatology and Therapy.
[6] A. Hauschild,et al. Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.
[7] G. Fabbrocini,et al. Long-Term Efficacy of Vismodegib After its Withdrawal and Patients’ Health-Related Quality of Life Using the Dermatology Life Quality Index (DLQI) , 2019, Dermatology and Therapy.
[8] S. Ibrahim,et al. Oral Hedgehog Pathway Inhibition as a Means for Ocular Salvage in Locally Advanced Intraorbital Basal Cell Carcinoma , 2019, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].
[9] D. Ratner,et al. Implementation of Systemic Hedgehog Inhibitors in Daily Practice as Neoadjuvant Therapy. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.